--News Direct--

Emyria Ltd (ASX:EMD) MD Michael Winlo tells Proactive the company has dosed its first patients in the pivotal Phase 3 clinical trial of lead drug candidate EMD-RX5. This marks an important milestone in the development of EMD-RX5 as the first potential over-the-counter (OTC) treatment for the symptoms of psychological distress.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/emyria-welcomes-dosing-of-first-patient-in-phase-3-anxiety-trial-737907967